Mr. Cohen was appointed to our board of directors in July 2025 and is a member of both the Audit and Compensation Committees. Mr. Cohen is an accredited public company director and seasoned medical technology executive with extensive experience in leading and scaling innovative healthcare companies. He currently serves on the boards of Kestra Medical Technologies (Nasdaq: KMTS), where he is Chair the Compensation Committee; InspireMD (Nasdaq: NSPR) as an Independent Director; Biobeat as Executive Chairman, Spiro Medical as Chairman, Archimedes Vascular as Chairman. Cohen also serves as a Venture Partner with Andera Partners and Sherpa Capital Partners. During 2025, Nalu Medical, and SoniVie where Mr. Cohen served as chairman were both sold in 2025 to Boston Scientific. From 2013 until late 2024, Mr. Cohen was Chief Executive Officer and a member of the board of Axonics, Inc. (Nasdaq: AXNX), where he led the company from inception to being recognized as the fastest-growing company in North America and oversaw its $3.7 billion acquisition by Boston Scientific. Earlier in his career, he served as Chairman of BioLife Solutions, Inc. (Nasdaq: BLFS) and held board positions at Spectrum Pharmaceuticals (Nasdaq: SPPI), LifeWatch (LIFE.SW), Syncroness, Inc. and for over 10 years as CEO and Chairman of Cardiac Science, Inc (DFIB). Mr. Cohen holds a B.S. in Business Management from Binghamton University in New York.